Skilarence

dimethyl fumarate · Almirall, S.A.
AUTHORISED IN THE EU

What Skilarence is used for

Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Skilarence
Active substance
dimethyl fumarate
Disease area
Psoriasis
Medicine group
Immunosuppressants
ATC code
L04AX07
Marketing authorisation holder
Almirall, S.A.
Authorised in the EU since
2017

Official information

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Skilarence used for?

Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.

What is the active substance in Skilarence?

Skilarence contains dimethyl fumarate.

Who makes Skilarence?

The EU marketing authorisation holder is Almirall, S.A..

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.